Bio Services Online Learning Event: From Deal Announcement to De-SPAC Process

December 9, 2021
1:00 PM

To Register:

A private biotech that announces a definitive agreement with a SPAC jumps into the public investor spotlight and faces that attention with fewer guardrails than the IPO process, plus a need to transform board, investor, and regulatory relations. Given that most SPAC merger deals also involve follow-on PIPE investment rounds or other transactions, the full fundraising benefits of the deal strategy require a smooth de-SPAC process that a private biotech would never have encountered before. Join this webinar to learn best practices for navigating from SPAC deal announcement through de-SPAC process to regular life managing a publicly traded company. Interact with the following dealmaking experts to ask them your own questions during the session.

— Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY

— Julia Forbess, Partner, Fenwick & West LLP
— Jonas Grossman, President and Managing Partner, Chardan
— Jeet Mahal, Chief Financial and Business Officer, Jasper Therapeutics
— Anna Mowry, Chief Financial Officer, Nautilus Bio

This session is part of the "Anatomy of a SPAC Deal" Webinar Series,
sponsored by Chardan.

Learn More » View All Events »